You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Tools to Get to LDL-C Target With Better Adherence: The Experts Share Experiences With New Therapies

  • Authors: Kausik K. Ray, MBChB, MD, MPhil, FRCP; Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH; Brian A. Ference, MD, MPhil, MSc, FACC, FESC; Anne Tybjærg-Hansen, MD, DMSc
  • CPD Released: 9/20/2022
  • Valid for credit through: 9/20/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.75 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and diabetologists/endocrinologists.

The goal of this activity is that the learner will be better able to appropriately use lipid-lowering therapy in patients at high and very-high cardiovascular risk to achieve LDL-C goals and maintain adherence for the long term.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Challenges to medication adherence in patients prescribed lipid-lowering therapy
  • Have greater competence related to
    • Selection of appropriate lipid-lowering therapy to achieve LDL-C targets
    • Selection of appropriate lipid-lowering therapy to overcome barriers to medication adherence


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Moderator

  • Kausik K. Ray, MBChB, MD, MPhil, FRCP

    President
    European Atherosclerosis Society
    Professor of Public Health and Honorary Consultant Cardiologist
    Director
    Imperial Centre for Cardiovascular Disease Prevention
    Deputy Director
    Imperial Clinical Trials Unit
    Head of Commercial Trials
    Imperial College London
    London, United Kingdom

    Disclosures

    Kausik K. Ray, MBChB, MD, MPhil, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: Abbott; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Cargene; CRISPR; Daiichi Sankyo, Inc.; Eli Lilly; Esperion Therapeutics, Inc.; Kowa Company Ltd.; New Amsterdam Pharma; Novartis; Novo Nordisk; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Resverlogix Corp; Sanofi; SCRIBE; Silence Therapeutics; Vaxxinity; Viatris
    Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Novartis; Novo Nordisk; Sanofi; Viatris
    Research funding from: Amgen, Inc.; Daiichi Sankyo, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Stock options from: Cargene; Pemi 31

Faculty

  • Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH

    President
    International Lipid Expert Panel (ILEP)
    President
    Polish Lipid Association (PoLA)
    Head and Professor
    Department of Preventive Cardiology and Lipidology
    Medical University of Lodz (MUL)
    Lodz, Poland;
    Head
    Cardiovascular Research Center
    University of Zielona Góra
    Zielona Góra, Poland

    Disclosures

    Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH, has the following relevant financial relationships:
    Consultant or advisor for: Adamed; Amgen, Inc.; Daiichi Sankyo, Inc.; Esperion Therapeutics, Inc.; Freia Pharmaceuticals; New Amsterdam; Novartis; Polfarmex; Sanofi; Viatris
    Speaker or member of speakers bureau for: Amgen, Inc.; Daiichi Sankyo, Inc.; Hebral; Kogen; KRKA; Polpharma; Novartis; Sanofi; Teva; Zentiva
    Research funding from: Amgen, Inc.; Sanofi; Viatris
    Contracted researcher for: Nomi Biotech Corporation (as CMO)
    Stock options from: Nomi Biotech Corporation

  • Brian A. Ference, MD, MPhil, MSc, FACC, FESC

    Director of Research (Professor) in Translational Therapeutics
    Executive Director
    Centre for Naturally Randomised Trials
    University of Cambridge
    Cambridge, United Kingdom

    Disclosures

    Brian A. Ference, MD, MPhil, MSc, FACC, FESC, has the following relevant financial relationships:
    Consultant or advisor for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; CiVi Pharma; Ionis Pharmaceuticals; Daiichi Sankyo; dalCOR; Eli Lilly; KrKa Pharmaceuticals; Merck; Mylan; Novartis; NovoNordisk; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; The Medicines Co.; Viatris
    Research funding from: Amgen; Esperion Therapeutics, Merck; Novartis; Pfizer

  • Anne Tybjærg-Hansen, MD, DMSc

    Professor
    Chief Physician
    Copenhagen University Hospital and Faculty of Health and Medical Sciences
    University of Copenhagen
    Copenhagen, Denmark

    Disclosures

    Anne Tybjærg-Hansen, MD, DMSc, has the following relevant financial relationships:
    Consultant or advisor for: Akcea Therapeutics; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Draupnir Bio; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi; Silence Therapeutics
    Speaker or member of speakers bureau for: Akcea Therapeutics; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Draupnir Bio; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi; Silence Therapeutics

Editor

  • Anne M. Sendaydiego, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Tools to Get to LDL-C Target With Better Adherence: The Experts Share Experiences With New Therapies

Authors: Kausik K. Ray, MBChB, MD, MPhil, FRCP; Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH; Brian A. Ference, MD, MPhil, MSc, FACC, FESC; Anne Tybjærg-Hansen, MD, DMScFaculty and Disclosures

CPD Released: 9/20/2022

Valid for credit through: 9/20/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

The Need to Treat to Target for the Long Term and Not the Short Term

Dr Ference discusses why it is important to recognize cumulative atherosclerotic cardiovascular disease (ASCVD) risk.
Brian A. Ference, MD, MPhil, MSc, FACC, FESC

Adherence in LDL-C Lowering and Why Patients Do Not Maintain Therapies

Dr Banach reviews challenges to medication adherence with lipid-lowering therapies.
Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPH

Value of Oral Therapies to Get to LDL-C Target

Dr Tybjærg-Hansen outlines the role of oral therapies in lipid management.
Anne Tybjærg-Hansen, MD, DMSc

Value of Monoclonal Antibodies in Getting Patients to LDL-C Target

Dr Ray outlines the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in lipid management.
Kausik K. Ray, MBChB, MD, MPhil, FRCP

Value of siRNA Therapies in Getting Patients to LDL-C Target

Dr Ray considers how novel small interfering RNA (siRNA) therapies can help to achieve LDL-C goals.
Kausik K. Ray, MBChB, MD, MPhil, FRCP
 

Educational Impact Challenge

The goal of this activity is that the learner will be better able to appropriately use lipid-lowering therapy in patients at high and very-high cardiovascular risk to achieve LDL-C goals and maintain adherence for the long-term.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print